EVA Pharma is proud to participate in this year’s DUPHAT UAE at its 2023 edition in Dubai, from 10-12th January.
We invite you to meet our team at hall 2 - stand 2D10.&nbsp;

medium_MicrosoftTeams-image (97).png

small_MicrosoftTeams-image (97).png

thumbnail_MicrosoftTeams-image (97).png

MicrosoftTeams-image (97).png

DUPHAT, UAE 2023

EVA Pharma is proud to announce our participation in the UN Climate Change Conference (COP27) in Sharm el-Sheikh. ​
We invite you to meet our team at hall A2 - booth H3; to discuss initiatives for a better climate for the next generations and sustainable development goals for local patients' needs. ​
&nbsp;
book a meeting: https://forms.office.com/r/vB4MBW5XXi&nbsp;&nbsp;

large_Cop 27 Wide copy.png

medium_Cop 27 Wide copy.png

small_Cop 27 Wide copy.png

thumbnail_Cop 27 Wide copy.png

Cop 27 Wide copy.png

      COP27- Sharm El Sheikh - Egypt 2022                                                     

EVA Pharma is proud to participate in this year’s CPHI , a global gathering that brings together pharmaceutical companies from around the world to discuss the latest industry trends and innovations.&nbsp;
&nbsp;
The event will be held in Frankfurt, Germany , from 1 – 3 November 2022 . Come meet EVA Pharma at 40C50

medium_MicrosoftTeams-image (18).png

small_MicrosoftTeams-image (18).png

thumbnail_MicrosoftTeams-image (18).png

MicrosoftTeams-image (18).png

CPHI - Frankfurt, Germany 2022 . 

<div class="OutlineElement Ltr SCXW200050207 BCX9" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; overflow: visible; cursor: text; clear: both; position: relative; direction: ltr; font-family: 'Segoe UI', 'Segoe UI Web', Arial, Verdana, sans-serif; font-size: 12px; background-color: #ffffff;">
<p class="Paragraph SCXW200050207 BCX9" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; overflow-wrap: break-word; white-space: pre-wrap; vertical-align: baseline; font-kerning: none; background-color: transparent; color: windowtext;"><span class="TextRun SCXW200050207 BCX9" lang="EN-US" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; font-variant-ligatures: none !important; font-size: 11pt; line-height: 19.425px; font-family: Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif; font-weight: bold;" xml:lang="EN-US" data-contrast="auto">EVA<span class="TextRun SCXW200050207 BCX9" lang="EN-US" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; font-variant-ligatures: none !important; font-size: 11pt; line-height: 19.425px; font-family: Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif;" xml:lang="EN-US" data-contrast="auto"> <span class="TextRun SCXW200050207 BCX9" lang="EN-US" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; font-variant-ligatures: none !important; font-size: 11pt; line-height: 19.425px; font-family: Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif; font-weight: bold;" xml:lang="EN-US" data-contrast="auto">Pharma<span class="TextRun SCXW200050207 BCX9" lang="EN-US" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; font-variant-ligatures: none !important; font-size: 11pt; line-height: 19.425px; font-family: Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif;" xml:lang="EN-US" data-contrast="auto"> is participating as a sponsor for the first time at the European Association for the Study of Diabetes’ (EASD) 2022 Annual Meeting, which will be held in Stockholm, Sweden, from 19 to 23 September.<span class="EOP SCXW200050207 BCX9" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; font-size: 11pt; line-height: 19.425px; font-family: Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif;" data-ccp-props="{&quot;201341983&quot;:0,&quot;335559740&quot;:259}">&nbsp;
</div>
<div class="OutlineElement Ltr SCXW200050207 BCX9" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; overflow: visible; cursor: text; clear: both; position: relative; direction: ltr; font-family: 'Segoe UI', 'Segoe UI Web', Arial, Verdana, sans-serif; font-size: 12px; background-color: #ffffff;">
<p class="Paragraph SCXW200050207 BCX9" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; overflow-wrap: break-word; white-space: pre-wrap; vertical-align: baseline; font-kerning: none; background-color: transparent; color: windowtext;"><span class="EOP SCXW200050207 BCX9" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; font-size: 11pt; line-height: 19.425px; font-family: Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif;" data-ccp-props="{&quot;201341983&quot;:0,&quot;335559740&quot;:259}">&nbsp;
</div>
<div class="OutlineElement Ltr SCXW200050207 BCX9" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; overflow: visible; cursor: text; clear: both; position: relative; direction: ltr; font-family: 'Segoe UI', 'Segoe UI Web', Arial, Verdana, sans-serif; font-size: 12px; background-color: #ffffff;">
<p class="Paragraph SCXW200050207 BCX9" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; overflow-wrap: break-word; white-space: pre-wrap; vertical-align: baseline; font-kerning: none; background-color: transparent; color: windowtext;"><span class="TextRun SCXW200050207 BCX9" lang="EN-US" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; font-variant-ligatures: none !important; font-size: 11pt; line-height: 19.425px; font-family: Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif;" xml:lang="EN-US" data-contrast="auto">The EASD holds its Annual Meeting in a different European city each year, with more than 15,000 delegates from over 130 countries attending. The scientific program at this year’s 58th Annual Meeting includes more than 1,200 talks and presentations on the latest results in diabetes research by leading experts in the field.<span class="EOP SCXW200050207 BCX9" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; font-size: 11pt; line-height: 19.425px; font-family: Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif;" data-ccp-props="{&quot;201341983&quot;:0,&quot;335559740&quot;:259}"> 
</div>

European Association for the Study of Diabetes’ Annual Meeting 2022 

medium_MicrosoftTeams-image (10).png

small_MicrosoftTeams-image (10).png

thumbnail_MicrosoftTeams-image (10).png

MicrosoftTeams-image (10).png

European Association for the Study of Diabetes’ Annual Meeting 2022             

EASD  Annual Meeting 2022 

Happening at EVA Pharma

EVA Pharma’s roots in Egypt stretch back over a hundred years.

Our History

Our experienced leadership team keeps us on track.

Meet our Leaders

EVA Pharma’s success is based on its dynamic team, Our people are our power.

Life at EVA Pharma

From the country of civilization and the source of the Nile from the heart of Aswan, we participated in the press conference to announce the localization and availability of the latest oncology and blood diseases treatments
As a serious and important step in the process of providing treatments for the Egyptian and Arab patients
The conference was held in the presence of a group of professors of oncology and hematology
Prof. Dr. Samir Shehata, Professor of Oncology at the Faculty of Medicine, Assiut University
Prof. Dr. Ibtisam Saad El-Din, Professor of Oncology, Faculty of Medicine, Cairo University
Prof. Dr. Hisham Tawfik, Professor of Oncology, Faculty of Medicine, Tanta University
Prof. Dr. Mohamed Abdel Moneim, Professor of Oncology and Hematology at the National Cancer Institute
Prof. Dr. Raafat Abdel Fattah, Professor of Hematology and Bone Marrow Transplantation at the National Institute of Diseases

Localization and availability of oncology and blood diseases treatments

Event

medium_MicrosoftTeams-image (131).png

small_MicrosoftTeams-image (131).png

thumbnail_MicrosoftTeams-image (131).png

MicrosoftTeams-image (131).png

Localization of oncology and blood diseases treatments

One of the most beautiful cities in Egypt, the city of Luxor, and from inside the Luxor Temple, we are proud of our participation in the press conference to announce the launch of the second edition of Urology guidelines.
The conference was held under the auspices of Prof. Dr. Khaled Abdel Ghaffar, Minister of Health and Population, and Prof. Dr. Mohamed Awad Taj El-Din, Advisor to the President of the Republic for Health Affairs, in the presence of a group of professors of urology,
Prof. Dr. Sherif Mourad, Professor of Urology, Ain Shams Medicine, and Rapporteur of the Guidelines Committee,
Prof. Dr. Hassan Ayo El-Enein, President of the Egyptian Urological Society,
Prof. Dr. Mohamed Shalaby, Professor of Urology, Assiut Medicine,and
Prof. Dr. Rafik Al-Halabi, Professor of Urology, Ain Shams Medicine,
In the presence of more than 100 doctors, they participated in developing the guidelines

celebrating the launch of the second edition of urology guidelines  

medium_MicrosoftTeams-image (130).png

small_MicrosoftTeams-image (130).png

thumbnail_MicrosoftTeams-image (130).png

MicrosoftTeams-image (130).png

Celebrating the second edition of urology guidelines  

Cairo,5th March
Oncology experts hail moves to manufacture cancer treatments locally
Oncology professors participating in last month’s 14th International Conference of the Department of Oncology and Nuclear Medicine at the Faculty of Medicine, Assiut University, praised the steps taken by some Egyptian pharmaceutical companies to localize oncology drug manufacturing within the country.
Dr. Samir Shehata, professor of oncology at the Faculty of Medicine, Assiut University, commented: “We encourage all Egyptian companies to enter the field of manufacturing oncology drugs, to provide medicine in a sustainable way and at low prices.”
He added, in his statements on the sidelines of the conference, that presidential campaigns and initiatives have led to a decrease in death rates among oncology patients, but this decrease requires continuity in the provision of treatments, which represents a great burden on the state.
Dr. Ibtisam Saad El-Din, professor of oncology at the Faculty of Medicine, Cairo University, said that the production of oncology drugs within Egyptian factories will create a perpetual supply at an affordable price. She explained that such drugs are used in the treatment of many tumors. This includes advanced breast cancer, especially the hormone-positive type, which represents about 75% of breast cancer cases among women.
She pointed out that the treatments are manufactured inside Egypt by an Egyptian company with the same efficiency and at a lower cost than imported medicine.
Dr. Mohamed Abdel Moaty, professor of oncology and hematology at the National Institute of Cancer at Cairo University, said that multiple myeloma a rare form of cancer, representing 2% of tumors in general and 10% of tumors of the blood. It is treated via a number of directed and immune drugs.
He explained that there are 160,000 cases of multiple myeloma worldwide, with an incidence rate of 1 per 100,000 people. In Egypt, 800 cases are diagnosed annually, at approximately the same rate as the global level, and the accumulated cases number about 1,700.
Dr. Raafat Abdel-Fattah, professor of hematology and bone marrow transplantation at the National Institute of Cancer at Cairo University, said that Egypt manufactures around 90% of the &nbsp;medicines it needs. In the field of tumors and malignant blood diseases, the country imports about 95% of its drug needs, he added, so localizing the manufacture of oncology drugs and medicines for malignant blood diseases is a breakthrough in the treatment of these diseases.
He added that providing modern treatments such as lenalidomide in Egypt is the best option for treating blood diseases such as bone marrow cancer or multiple myeloma.
Dr. Hisham Tawfik, professor of oncology at the Faculty of Medicine, Tanta University, said that the localization of the pharmaceutical industry to Egypt is in line with the state's sustainable development efforts and Egypt's 2030 strategy.
He added that the localization of the pharmaceutical industry to Egypt has three benefits, namely continuity in the provision of medicines, provision of medicines at low prices, and a reduction in pressure on forex reserves.
Dr. Amjad Talaat, General Manager of the Specialized Medicines Unit at EVA Pharma, said that the company is working to provide the latest medicines, in cooperation with the MARC Center for Scientific Research and with international firms. In doing so, EVA Pharma is contributing to the localization of the pharmaceutical industry to Egypt, he said.
Dr. Talaat noted that the company has recently moved towards manufacturing targeted drugs and immunosuppressants and has allocated a factory to produce these drugs, as well as oncology and blood disease medications. The facility, which operates using the latest international technology, ensures continuity in provision of these medicines to consumers in Egypt, or in other Arab or African countries, with the highest efficiency and at an appropriate price.

large_MicrosoftTeams-image (146).png

medium_MicrosoftTeams-image (146).png

small_MicrosoftTeams-image (146).png

thumbnail_MicrosoftTeams-image (146).png

MicrosoftTeams-image (146).png

Oncology experts hail moves to manufacture cancer treatments locally.

Cairo,3rd of Feb2023&nbsp;
The Egyptian Association for Urology Research, in cooperation with the Supreme Council of University Hospitals and the Egyptian Medical Association, and sponsored by EVA Pharma, has launched the second edition of the Egyptian guidelines for the treatment of urological diseases, a critical area of specialization.
Dr. Mohamed Awad Taj El-Din, presidential adviser for health affairs, stressed the importance of putting in place national guidelines and guidelines for various medical specialties that help patients obtain the best medical care.
He said that establishing guidelines for various diseases ensure the optimal use of antibiotics in terms of type and duration, helping prevent antibiotic resistance. He added that the Egyptian Society of Chest Diseases and Tuberculosis has set guidelines for respiratory infections.
Dr. Sherif Murad, professor of urology at Ain Shams University and rapporteur for the Egyptian Urology Guidelines Committee, said that the committee began work in November 2019, as a result of the efforts of the Egyptian Urology Association and the Supreme Council of University Hospitals, with the support of the Egyptian Medical Association. Formed by a decree from Dr. Khaled Abdel Ghaffar, then minister of higher education and scientific research, the committee includes a number of specialized academics among its members and has 14 sub-committees.
Murad said that the first edition of the guidelines was launched in 2021 to serve as a reference for urologists and others for whom it would be relevant, include those working on cancer or male infertility.
The committee continues to update the guidelines periodically, in line with international medical trends, and to keep abreast of updates in the specialty, Murad said, so that the guidelines retain their value.
The goal of the committee at this stage is to unify the guidelines in the various health facilities affiliated with different authorities and ministries in all governorates, he added, in order to ensure equality between patients and to improve recovery rates.
Dr. Muhammad Shalaby, professor of urology, said that although there are international guidelines in the specialty of urology, some of them are not commensurate with the medical capabilities available at health facilities
Many surgeries abroad currently depend on the use of robots and modern endoscopes, he said, and these capabilities are not available in some Egyptian establishments, especially in the areas outside Cairo.
The nature of urinary tract diseases is different in Egypt than abroad due to climatic conditions and the spread of some diseases, Shalaby also said. For example, there are some cases of kidney stones among children as young as 6 months old.
He noted that the launch of the second edition of the urological guidelines was attended by more than 100 doctors.
The committee also sought the assistance of expert Alaa Ghoneimi, professor of pediatric surgery at the University of Paris, he said.
Shalaby also praised the efforts of EVA Pharma, an Egyptian pharmaceutical company which provides Egyptian patients with treatments of high quality and at reasonable prices.
For his part, Dr. Rafiq Al-Halabi, professor of urology at the Faculty of Medicine at Ain Shams University, said that the existence of guidelines for dealing with urological cases is beneficial for patients, both at the diagnosis and treatment stages.
The guidelines are also beneficial for doctors, allowing them to provide the most appropriate treatment methods in each case, preventing potential professional mistakes and exposure to legal risk.
He emphasized that the results of the publication of the first version of the guidelines was very good, and many young doctors working in the specialty sought help from the publication. The second version was the result of an integrated effort over months to include everything that is part of the specialty, with the addition of infections, testicular cancers and adrenal gland diseases.
Al-Halabi said that kidney stones, kidney and bladder cancer, and prostate enlargement are among the most common diseases of the urinary tract among men, and that the incidence of prostate tumors, both benign and malignant, increases over the age of 50.

large_MicrosoftTeams-image (132).png

medium_MicrosoftTeams-image (132).png

small_MicrosoftTeams-image (132).png

thumbnail_MicrosoftTeams-image (132).png

MicrosoftTeams-image (132).png

launch of the second edition of Egypt’s urology guidelines 

medium_MicrosoftTeams-image (99).png

small_MicrosoftTeams-image (99).png

thumbnail_MicrosoftTeams-image (99).png

MicrosoftTeams-image (99).png

“Hyatk Mkmla” campaign

For the first time, Lilly will supply API at a significantly reduced price along with pro-bono technical assistance, enabling EVA Pharma to manufacture and supply insulin to at least one million people in lower income countries
&nbsp;
INDIANAPOLIS and CAIRO,&nbsp; December 14, 2022 – Eli Lilly and Company (NYSE: LLY) and EVA Pharma&nbsp; announced today a collaboration to deliver a sustainable supply of high-quality, affordable human and analogue insulin to at least one million people living with type 1 and type 2 diabetes in low- to middle-income countries (LMICs), most of which are in Africa.
&nbsp;
In a first for Lilly, the company will supply its active pharmaceutical ingredient (API) for insulin at a significantly reduced price to EVA Pharma. Lilly will also provide a pro-bono technology transfer to enable EVA Pharma to formulate, fill and finish insulin vials and cartridges – establishing the company as a trusted manufacturer of these lifesaving products in Africa.
&nbsp;
EVA Pharma expects to begin distribution of the African-made insulin products within 18 months and to reach one million people per year by 2030. This collaboration is part of the Lilly 30x30 initiative, which aims to improve access to quality healthcare for 30 million people living in limited -resource settings, annually, by 2030
&nbsp;
“Our new collaboration with EVA Pharma reflects Lilly’s deep commitment to making equitable and affordable access to insulin a reality for people living with diabetes in low- and middle-income countries,” said Ilya Yuffa, president of Lilly International. “This latest initiative from Lilly will empower&nbsp; local manufacturing, finishing and&nbsp; distribution of quality insulin – in Africa – which will transform communities and make life better for people throughout the continent.”
&nbsp;
“EVA Pharma is committed to empowering the fight for health and well-being as a human right,” said Riad Armanious, CEO of EVA Pharma. “People suffering from diabetes in LMICs experience daily challenges in accessing treatment. We feel blessed to collaborate with the team at Lilly. Combining our African reach, state-of-the-art facilities, and Lilly’s deep expertise in diabetes care, we aim to treat at least one million patients by 2030 who otherwise may not have access to life-saving medication.”
&nbsp;
According to the IDF Diabetes Atlas, the total number of people with diabetes in Africa is expected to increase 129% by 2045, reaching 55 million people.
&nbsp;
&nbsp;
&nbsp;
&nbsp;WHO established the Global Diabetes Compact in 2021, a global initiative to support countries in implementing effective programs for the prevention and management of diabetes, one tenet of which includes engaging with the private sector to expand access to products that will improve the lives of people living with diabetes. The dialogues with WHO encourage implementation of and accountability for the commitments and contributions toward improving access to insulin
&nbsp;
“The success of these commitments to increase access for people living with diabetes is an important step in the right direction, but global engagement will need to be translated into implementation in regions and countries,” said WHO Director for Noncommunicable Disease, Dr Bente Mikkelsen. “This is the starting point the hope is to have insulin and diabetes devices as part of Essential Benefit Packages in low- and middle- income countries towards achieving Universal Health Coverage.”
&nbsp;
&nbsp;
&nbsp;
Lilly will work with EVA Pharma to ensure that their products meet the high-quality standards set for WHO prequalification, which has become a global symbol for safety, quality and efficacy.
&nbsp;
&nbsp;
&nbsp;
&nbsp;About Lilly&nbsp;
&nbsp;
&nbsp;
Lilly unites caring with discovery to create medicines that make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 47 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer’s disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/newsroom or follow us on Facebook, Instagram and LinkedIn.
About EVA Pharma
EVA Pharma empowers the fight for health and well-being in communities around the world.
With a 5,000-strong team of professionals, the company produces more than one million healthcare products a day at its state-of-the-art manufacturing facilities, which are equipped with cutting-edge technology, are internationally recognized for innovation, and have been approved by multiple regulatory agencies.
The company’s product portfolio focuses on pressing, yet unmet, disease areas, such as diabetes and cardiovascular diseases, oncology, neuroscience, ophthalmology, anti-infectives, bone and pain, hepatology, and reproductive health, to meet both local and international demand.
EVA Pharma is one of the fastest-growing healthcare companies in the Middle East and Africa, with an extensive pan-African presence, while operating in more than 40 countries worldwide.
For more information, please visit: www.evapharma.com &amp; https://www.evapharma.com/newsroom or follow us on Facebook, LinkedIn &amp; Instagram&nbsp;&nbsp;
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about a collaboration between Lilly and EVA Pharma and its potential benefits and reflects Lilly’s current beliefs and expectations. However, as with any such undertaking, there are substantial risks and uncertainties in the process of drug research, development and commercialization. Among other things, there can be no guarantee that Lilly will realize the expected benefits of the collaboration, that the collaboration will succeed, or that Lilly will execute its strategy as expected. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly’s expectations, see Lilly’s Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
&nbsp;

large_MicrosoftTeams-image (68).png

medium_MicrosoftTeams-image (68).png

small_MicrosoftTeams-image (68).png

thumbnail_MicrosoftTeams-image (68).png

MicrosoftTeams-image (68).png

 Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa

Cairo,November 29th- EVA Pharma cooperates with Egypt’s health ministry, UNAIDS on launch of HIV awareness campaign
&nbsp;
The National AIDS Control Program at Egypt’s Ministry of Health and Population, in cooperation with the Joint United Nations Programme on HIV/AIDS (UNAIDS) and with leading pharmaceutical company EVA Pharma, has launched a new campaign to fight discrimination against people infected with HIV and address societal fears around the disease.
The “Zay Ay Marad” (“Like Any Disease”) campaign was launched in conjunction with World AIDS Day, which falls on December 1 each year.
Dr. Hossam Abdel Ghaffar, the official spokesman for the Ministry of Health and Population, said that Egypt is among the countries with a low rate of people infected with human immunodeficiency virus (HIV). In addition, while the COVID-19 pandemic negatively affected the provision of treatment for people living with HIV in many countries, Egypt’s national program to combat AIDS was not affected, he said. In fact, there was an expansion in the umbrella of services provided by the program, and in the provision of the most up-to-date treatments to patients.
&nbsp;
Dr. Abdel Ghaffar stressed the importance of the new campaign in providing detailed information related to the disease and the methods of transmission in order to prevent discrimination against patients and to change the mindset that the infection is a "defect," as is sometimes said. Dr. Abdel Ghaffar pointed out that the disease is transmitted in several ways, including via blood contaminated with the virus, by using injection tools that were used by a person infected with the virus, through sexual relations with an infected person, or from an infected mother to her child during pregnancy or breastfeeding.
Dr. Heba El-Sayed, director of the National AIDS Control Program, said that the “Zay Ay Marad” campaign was launched in order to educate Egyptians that people living with HIV do not transmit the infection through normal daily interaction, in order to stop the discrimination against people infected with the virus.
Dr. El-Sayed, speaking at the campaign launch ceremony, said that the program provides all necessary services to patients infected with the virus free of charge, including examination and counseling related to the virus, and in strict confidentiality. It also provides integrated social support for people infected with the virus and their families, and clinical care for those infected via treatment centers at specialized fever hospitals in all Egyptian governorates.
&nbsp;
She added that a hotline is provided for those infected with HIV or those who have queries about it, on the numbers 0233152802, 0233152801, and 09007008000.
&nbsp;
The program aims to coordinate efforts with all parties to combat the disease, reduce infections, and maintain Egypt's status as a country with a low infection rate, while striving to eradicate AIDS in Egypt and achieve the 2030 Sustainable Development Goals, she said.
She stressed that Egypt is one of the leading countries in the field of AIDS medicines, and that thanks to companies such as EVA Pharma, Egypt is now able to provide treatment for 97% of people living with the illness through locally manufactured medicines, whereas previously all medication had been imported.
Dr. Walid Kamal, director of the Joint United Nations Programme on HIV/AIDS (UNAIDS) in Egypt, praised the efforts of the Egyptian state in combating HIV, and the cooperation of the national program with all partner agencies to serve patients, stressing that the celebration of World AIDS Day and the launch of the campaign aims to combat discrimination against people living with the virus.
The Egyptian state program is expanding the provision of examination services and health advice, in cooperation with the United Nations, to make the service available to any patient who needs it, in a way that contributes to further limiting the spread of the disease, Dr. Kamal said, noting that Egypt is one of the first countries in the Middle East to provide free treatment and services for HIV patients.
Dr. Kamal explained that the "Zay Ay Marad" campaign will organize many awareness activities on social media and established media to publicize correct information about the disease, fight discrimination, and raise awareness of HIV, which leads to AIDS.
He noted the Egyptian state's keenness to provide the latest pioneering treatments in line with new developments, in a way that improves the health condition of patients, limits the spread of the virus further, and facilitates patients' coexistence with the illness.
Dr. Riad Armanious, managing director of leading national pharmaceutical company EVA Pharma, expressed his enthusiasm for the cooperation with the health ministry and with UNAIDS. He said that the campaign’s name was selected because the HIV virus that causes AIDS is “like any disease” in the way it is spread, diagnosed, and the availability of treatment, and the patient’s right to psychological support and to live without discrimination.
Dr. Armanious added, in his speech at the launch ceremony, that the launch of the campaign is an important day to support health as a human right, pointing to the availability of an integrated treatment program in which people infected with HIV continue to live full lives. He also said that he appreciated Egypt’s efforts in providing an integrated program that treats patients with complete confidentiality and provides treatment and testing free of charge.&nbsp;
He noted that EVA contributes to raising awareness of the disease, as well as developing model clinics to treat this type of virus and training doctors on the topic.

large_MicrosoftTeams-image (58).png

medium_MicrosoftTeams-image (58).png

small_MicrosoftTeams-image (58).png

thumbnail_MicrosoftTeams-image (58).png

MicrosoftTeams-image (58).png

EVA Pharma cooperates with Egypt’s health ministry, UNAIDS on launch of HIV awareness campaign

Cairo-14 November- Leading pharmaceutical company EVA Pharma, which has a presence in over 40 countries worldwide, organized a series of events last week to celebrate World Diabetes Awareness Day, with the participation of several key national stakeholders.
EVA Pharma and Egypt Healthcare Authority cooperated to implement the “Sokarak Mazboot” campaign to raise awareness and conduct free examinations for diabetic patients at the Medical Complex building, the June 30 International Center for Nephrology and Tract Diseases, and at several other health facilities.
Dr. Mohamed Nashat, Director of the Secondary Care Department at the Egypt Healthcare Authority and Acting Deputy Director of the Medical Complex said that the campaign served many of the patients of the Medical Complex and the June 30 Center for free. Educational events about managing diabetes were also held at 32 healthcare centers and family medicine units.
EVA Pharma, in cooperation with presidential development initiative <a name="_Hlk120111349"></a>Haya Karima, also organized three convoys to conduct free medical examinations, with the company donating various diabetes and peripheral neuritis treatments to support the efforts.
EVA Pharma is keen to mark World Diabetes Awareness Day as part of the company’s commitment to social responsibility, said Dr. George Maher, EVA Pharma’s Marketing Director. The company’s role is not limited to providing the latest and most effective medical treatments in a variety of fields, including diabetes, he affirmed; it also extends to cooperation with all official authorities, and with medical associations and institutions, for the benefit of patients, through donating innovative treatments and organizing awareness sessions and other events.

large_MicrosoftTeams-image (70).png

medium_MicrosoftTeams-image (70).png

small_MicrosoftTeams-image (70).png

thumbnail_MicrosoftTeams-image (70).png

MicrosoftTeams-image (70).png

EVA Pharma celebrates World Diabetes Day by joint awareness campaigns with Haya Karima and Egypt Healthcare Authority

Cairo,october 14,2022-&nbsp;Leading pharmaceutical company EVA Pharma has introduced two new inhaler treatments to control chest allergy diseases and chronic obstructive pulmonary disease. The first product, Salmetocort, contains a number of active substances, including fluticasone propionate (cortisone) and salmeterol. The second product, Inhalex spray, contains the active ingredient tiotropium.
Specialists in pulmonary diseases from various universities participated in the press event marking the launch of the products. For his part, Dr. Mohamed Awad Tag El-Din, professor of pulmonary diseases and adviser to the president for health affairs, praised the decision to bring the new products to the market to treat pulmonary diseases with advanced technology, high quality and reasonable prices.
The specialist said that the Egyptian experience in dealing with the COVID-19 crisis has proven successful thanks to several factors, including the efforts of drug companies to provide COVID-19 treatments, as well as the provision of treatments for other communicable diseases, which ensured patients did not feel that there was a shortage of medicines.
He stressed that there are presidential directives to localize the modern pharmaceutical industry in Egypt, adding: “Many countries around the world have faced shortages, whether in medicines, medical supplies or vaccines, as a result of the interruption to the supply chains, the cessation of manufacturing, and the decisions of some foreign companies to stop exporting to meet their local needs.”
Dr. Adel Khattab, professor of pulmonary diseases at Ain Shams University and a member of the Supreme Committee for Respiratory Viruses at the Ministry of Higher Education, praised EVA Pharma for providing combined medicines that contain bronchodilators and anti-inflammatory drugs at an affordable price and international quality.
He explained that symptoms of chest allergies are quite common and can be worse at night or early in the morning and vary with time and in severity. They can intensify with viral infections, exercise, exposure to allergens, changes in weather, laughter, or irritants such as car exhaust fumes, smoke, or strong odors.
For his part, Dr. Mohamed Hantira, professor of pulmonary diseases at the Faculty of Medicine at Tanta University, said that chest allergy (asthma) is one of the most common respiratory diseases worldwide, affecting between 1% and 18% of the population, depending on the country.
He said that the common symptoms of both chest allergy and pulmonary embolism are coughing, sneezing, and difficulty breathing, stressing that the COVID-19 pandemic showed the importance of preserving the integrity of the lungs in order to avoid viral infections.
Dr. George Maher, General Manager of EVA Pharma, confirmed that the firm is working on research and development to provide the latest treatments for patients in Arab and African countries, adding: “We believe that access to medicine is a human right.”
He pointed to the company's interest in providing treatments for pulmonary diseases and in providing modern inhalers at a reasonable price for the patient, adding that the two new products that have just been released are the beginning of a production line for a group of medicines in the field of respiratory nebulizers.

large_MicrosoftTeams-image (78).png

medium_MicrosoftTeams-image (78).png

small_MicrosoftTeams-image (78).png

thumbnail_MicrosoftTeams-image (78).png

MicrosoftTeams-image (78).png

EVA Pharma launches international-quality treatments for chest allergy and pulmonary embolism

thumbnail_3.png

3.png

Eva Pharma launches its first production of "poultry medicines" before the season of «winter diseases» 

large_pexels-kaboompics-com-6335@2x.png

medium_pexels-kaboompics-com-6335@2x.png

small_pexels-kaboompics-com-6335@2x.png

thumbnail_pexels-kaboompics-com-6335@2x.png

pexels-kaboompics-com-6335@2x.png

Are you a Journalist or Media Representative and need information about us? Please feel free to get in touch with our PR Team

Media Contact 

large_MicrosoftTeams-image (51).png

medium_MicrosoftTeams-image (51).png

small_MicrosoftTeams-image (51).png

thumbnail_MicrosoftTeams-image (51).png

MicrosoftTeams-image (51).png

Cairo, September 26th-<span class="TextRun SCXW253566663 BCX8" lang="EN-US" style="color: windowtext; white-space: pre-wrap; margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; font-size: 11pt; line-height: 19.425px; font-family: Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif; font-variant-ligatures: none !important;" xml:lang="EN-US" data-contrast="auto">In conjunction with the celebration of the World Pharmacist Day, which falls on September 25 of each year, «Eva Pharma», one of the leading pharmaceutical companies, launched <span class="NormalTextRun AdvancedProofingIssueV2Themed SCXW253566663 BCX8" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; background-repeat: repeat-x; background-position: left bottom; background-image: var(--urlAdvancedProofingIssueV2, ); border-bottom: 1px solid transparent;">a number of events to serve and support workers in the pharmaceutical sector, in order to emphasize the important role of pharmacists in everything related to medicine from research, studies and manufacturing to pharmacological education for patients and clinical pharmacy.<span class="EOP SCXW253566663 BCX8" style="color: windowtext; white-space: pre-wrap; margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; font-size: 11pt; line-height: 19.425px; font-family: Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif;" data-ccp-props="{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}">&nbsp;
<div class="OutlineElement Ltr SCXW253566663 BCX8" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; overflow: visible; cursor: text; clear: both; position: relative; direction: ltr; font-family: 'Segoe UI', 'Segoe UI Web', Arial, Verdana, sans-serif; font-size: 12px; background-color: #ffffff;">
<p class="Paragraph SCXW253566663 BCX8" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; overflow-wrap: break-word; white-space: pre-wrap; vertical-align: baseline; font-kerning: none; background-color: transparent; color: windowtext;"><span class="TextRun SCXW253566663 BCX8" lang="EN-US" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; font-variant-ligatures: none !important; font-size: 11pt; line-height: 19.425px; font-family: Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif;" xml:lang="EN-US" data-contrast="auto">Dr. Ahmed <span class="NormalTextRun SpellingErrorV2Themed SCXW253566663 BCX8" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; background-repeat: repeat-x; background-position: left bottom; background-image: var(--urlSpellingErrorV2, ); border-bottom: 1px solid transparent;">ellewa, Director of Public Relations at Eva Pharma, stressed the company's interest in highlighting the role of the pharmacist as the first expert of the drug and an active member in the provision of medical service.<span class="EOP SCXW253566663 BCX8" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; font-size: 11pt; line-height: 19.425px; font-family: Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif;" data-ccp-props="{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}">&nbsp;
</div>
<div class="OutlineElement Ltr SCXW253566663 BCX8" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; overflow: visible; cursor: text; clear: both; position: relative; direction: ltr; font-family: 'Segoe UI', 'Segoe UI Web', Arial, Verdana, sans-serif; font-size: 12px; background-color: #ffffff;">
<p class="Paragraph SCXW253566663 BCX8" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; overflow-wrap: break-word; white-space: pre-wrap; vertical-align: baseline; font-kerning: none; background-color: transparent; color: windowtext;"><span class="EOP SCXW253566663 BCX8" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; font-size: 11pt; line-height: 19.425px; font-family: Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif;" data-ccp-props="{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}">&nbsp;
</div>
<div class="OutlineElement Ltr SCXW253566663 BCX8" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; overflow: visible; cursor: text; clear: both; position: relative; direction: ltr; font-family: 'Segoe UI', 'Segoe UI Web', Arial, Verdana, sans-serif; font-size: 12px; background-color: #ffffff;">
<p class="Paragraph SCXW253566663 BCX8" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; overflow-wrap: break-word; white-space: pre-wrap; vertical-align: baseline; font-kerning: none; background-color: transparent; color: windowtext;"><span class="TextRun SCXW253566663 BCX8" lang="EN-US" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; font-variant-ligatures: none !important; font-size: 11pt; line-height: 19.425px; font-family: Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif;" xml:lang="EN-US" data-contrast="auto">He added that the company cooperated with several entities to organize various activities on the occasion of the World Pharmacist Day, including sponsoring the closing ceremony of the Pharmaceutical Care Initiative - Distinguished Pharmaceutical Practices - 100 developmental projects, which is a free grant from the Drug Authority to pharmacists in Egypt where the number of trainees reached about 3700 pharmacists from different parties and employees of hospitals affiliated with a number of health bodies and sectors in the country.<span class="EOP SCXW253566663 BCX8" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; font-size: 11pt; line-height: 19.425px; font-family: Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif;" data-ccp-props="{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}">&nbsp;
</div>
<div class="OutlineElement Ltr SCXW253566663 BCX8" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; overflow: visible; cursor: text; clear: both; position: relative; direction: ltr; font-family: 'Segoe UI', 'Segoe UI Web', Arial, Verdana, sans-serif; font-size: 12px; background-color: #ffffff;">
<p class="Paragraph SCXW253566663 BCX8" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; overflow-wrap: break-word; white-space: pre-wrap; vertical-align: baseline; font-kerning: none; background-color: transparent; color: windowtext;"><span class="EOP SCXW253566663 BCX8" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; font-size: 11pt; line-height: 19.425px; font-family: Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif;" data-ccp-props="{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}">&nbsp;
</div>
<div class="OutlineElement Ltr SCXW253566663 BCX8" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; overflow: visible; cursor: text; clear: both; position: relative; direction: ltr; font-family: 'Segoe UI', 'Segoe UI Web', Arial, Verdana, sans-serif; font-size: 12px; background-color: #ffffff;">
<p class="Paragraph SCXW253566663 BCX8" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; overflow-wrap: break-word; white-space: pre-wrap; vertical-align: baseline; font-kerning: none; background-color: transparent; color: windowtext;"><span class="TextRun SCXW253566663 BCX8" lang="EN-US" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; font-variant-ligatures: none !important; font-size: 11pt; line-height: 19.425px; font-family: Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif;" xml:lang="EN-US" data-contrast="auto">Ellewa explained that training courses have been developed in health economics to introduce health policy frameworks and their role in the development of the health system, and how to choose the right drug based on its effectiveness and therapeutic and economic efficiency.<span class="EOP SCXW253566663 BCX8" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; font-size: 11pt; line-height: 19.425px; font-family: Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif;" data-ccp-props="{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}">&nbsp;
</div>
<div class="OutlineElement Ltr SCXW253566663 BCX8" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; overflow: visible; cursor: text; clear: both; position: relative; direction: ltr; font-family: 'Segoe UI', 'Segoe UI Web', Arial, Verdana, sans-serif; font-size: 12px; background-color: #ffffff;">
<p class="Paragraph SCXW253566663 BCX8" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; overflow-wrap: break-word; white-space: pre-wrap; vertical-align: baseline; font-kerning: none; background-color: transparent; color: windowtext;"><span class="TextRun SCXW253566663 BCX8" lang="EN-US" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; font-variant-ligatures: none !important; font-size: 11pt; line-height: 19.425px; font-family: Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif;" xml:lang="EN-US" data-contrast="auto">He also mentioned that EVA pharma has arranged several visits for students and pharmacists to the factories of Eva Pharma, which have received international approvals, and explained the latest methods of manufacturing the drug, while encouraging pharmacists on social media to share their various fields and clarify their influential role in society.<span class="EOP SCXW253566663 BCX8" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; font-size: 11pt; line-height: 19.425px; font-family: Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif;" data-ccp-props="{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}"> 
</div>

large_MicrosoftTeams-image (49).png

medium_MicrosoftTeams-image (49).png

small_MicrosoftTeams-image (49).png

thumbnail_MicrosoftTeams-image (49).png

MicrosoftTeams-image (49).png

«Eva Pharma» organizes intensive events in celebration of the World Pharmacist Day. 

Top News

Press Release

Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa

December 14, 2022

Latest News

Press Release

2023-03-05

Press Release

2023-02-03

Press Release

2022-12-19

Press Release

2022-12-14

Press Release

2022-11-29

Press Release

2022-11-14

Press Release

2022-10-14

Press Release

2022-09-28

Happening at EVA

10

Event

DUPHAT, UAE 2023

10

Event

06

Event

01

Event

19

Event

Check out our latest events

Event

Event

Event

Media Contact

Find out more about EVA Pharma

EVA Pharma’s roots in Egypt stretch back over a hundred years.

Our experienced leadership team keeps us on track.

EVA Pharma’s success is based on its dynamic team, Our people are our power.

© 2022 Eva Pharma All Rights Reserved - شركة ايفا فارما للادوية و المستلزمات الطبية